Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation to trastuzumab treatment

Ieni,A.; Giuffrè,G.; Lanzafame,S.; Nuciforo,G.; Curduman,M.; Villari,L.; Roz,E.; Certo,G.; Cabibi,D.; Salomone,E.; Labate,A.; Messina,D.; Franco,V.; Adamo,V.; Tuccari,G.

doi:10.3892/ol.2011.425

Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation to trastuzumab treatment

Authors:
- A. Ieni
- G. Giuffrè
- S. Lanzafame
- G. Nuciforo
- M. Curduman
- L. Villari
- E. Roz
- G. Certo
- D. Cabibi
- E. Salomone
- A. Labate
- D. Messina
- V. Franco
- V. Adamo
- G. Tuccari
View Affiliations

Affiliations: Department of Human Pathology, University of Messina, Messina 98125, Italy, Department of Human Pathology, University of Messina, Messina 98125, Italy, Department of Diagnostic-Forensic Pathology and Public Health, University of Catania, Polyclinic G. Rodolico, Catania, Italy, Humanitas Oncology Center, Catania, Italy, A.O.U. Vittorio Emanuele II, Catania, Italy, La Maddalena Oncology Hospital, Palermo, Italy, Cappellani Pathology Division, Messina, Italy, Department of Human Pathology, University of Palermo, A.O.U. Polyclinic Giaccone, Palermo, Italy, Pathology Division, Sant'Antonio Abate Hospital, Trapani, Italy
Published online on: September 20, 2011 https://doi.org/10.3892/ol.2011.425
Pages: 141-146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Little information from clinical trials is available regarding the efficacy of trastuzumab treatment in subcentimetric breast carcinomas (BCs). The aim of this study was to verify the existence of correlations between HER2 and hormone receptor status, Ki67 values, grade, histotype and node involvement in a cohort of pT1a,b BCs from an area not widely covered by screening campaigns. A total of 410 pT1a,b BC formalin‑fixed paraffin-embedded samples collected from eight Sicilian Anatomo-Pathological Units (APUs) were classified according to the WHO classification and tumour grading was established. Estrogen and progesterone receptor status, Ki67 labelling index and HER2 status were available. Relationships between immunohistochemical data and clinicopathological characteristics were investigated using the Chi-square test; the cohort was analysed with respect to pT1a and pT1b BC as well as to node status. Ductal infiltrating carcinoma was the prevalent histotype in the pT1a and pT1b stages; G2 was a more common tumour grade, with a range between 64.6% and 70% of pT1a and pT1b, respectively. Taking into consideration the lymph node involvement of pT1a,b BC, only 17.1% cases were node-positive without a relevant difference between pT1a and pT1b. No significant differences between pT1a and pT1b BC cases emerged in relation to Ki67 LI, hormone receptors and HER2 status. T1a,b BC cases were stratified by node involvement and a significant relationship was observed with grade as well as with HER2 status. A significant relationship for pT1a cases emerged only for tumour grade, while pT1b cases showed a significant correlation exclusively with HER2 status. Our data clearly support the operative guidelines of the National Comprehensive Cancer Network. Therefore, the combined treatment with trastuzumab plus chemotherapy should be administered only to patients with pT1b or larger BCs. In small HER2-positive pT1a or microinvasive BC, this therapy should be considered on a case‑by‑case basis, considering tumour grade as the first characteristic.

View Figures

View References

1	Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al: AJCC cancer staging handbook: TNM classification of malignant tumours. 6th edition. Wiley; New York: 2002, View Article : Google Scholar
2	Goldhirsch A, Gelber RD, Viale G, Colleoni M and Coates AS: Prediction of cancer outcome with microarrays. Lancet. 365:1685–1686. 2005. View Article : Google Scholar
3	Hanrahan EO, Valero V, Gonzalez-Angulo AM and Hortobagyi GN: Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol. 13:2113–2122. 2006. View Article : Google Scholar : PubMed/NCBI
4	Spector NL and Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 34:5838–5847. 2009. View Article : Google Scholar : PubMed/NCBI
5	Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F and Goldhirsch A: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 34:5693–5699. 2009. View Article : Google Scholar : PubMed/NCBI
6	Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA and Hortobagyi GN: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 34:5700–5706. 2009. View Article : Google Scholar : PubMed/NCBI
7	Burstein HJ and Winer EP: Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 34:5671–5673. 2009. View Article : Google Scholar
8	Crivellari D and Molino A: Small tumor size and node-negative HER2-positive breast cancer: a step forward for a better treatment? J Clin Oncol. 16:e2572010. View Article : Google Scholar : PubMed/NCBI
9	Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F and Goldhirsch A: Reply to D. Crivellari et al. J Clin Oncol. 16:e2582010. View Article : Google Scholar
10	Petrelli F and Barni S: Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate. Med Oncol. View Article : Google Scholar : 2010.PubMed/NCBI
11	Sciacca S, Sciacchitano S, Fidelbo M, Benedetto G, Madeddu A, Vasquez E, Cordio S, Caltavituro G, Castaing M, Cutello P, Pesce P, Ragusa R, Sciacchitano C and Torrisi A and Torrisi A: Breast neoplasms in the Province of Catania: data from the Integrated Neoplasms Registry, Catania-Messina-Siracusa, 2003–2005. Epidemiol Prev. 33:59–69. 2009.PubMed/NCBI
12	Rosen PP and Oberman H: Tumours of the mammary gland. Washington DC: Armed Forces Institute of Pathology; 1993
13	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 41:151–152. 2002.
14	Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K and Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 3:923–930. 2003.
15	Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO and Gelmon K: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 35:5697–5704. 2008. View Article : Google Scholar : PubMed/NCBI
16	Giordano L, Giorgi D, Piccini P, Ventura L, Stefanini V, Senore C, Paci E and Segnan N: Time trends of process and impact indicators in Italian mammography screening programmes 1996–2004. Epidemiol Prev. 31:21–32. 2007.
17	Giorgi D, Giordano L, Ventura L, Frigerio A, Paci E and Zappa M: Mammography screening in Italy: 2005 survey and 2006 preliminary data. Epidemiol Prev. 32:7–22. 2008.PubMed/NCBI